Torrent Pharma, one of India’s leading pharmaceutical companies, has appointed Manish Kainth as its Chief Human Resources Officer (CHRO).
The move comes at a pivotal time as Torrent Pharma continues its global expansion and deepens its focus on building a future-ready workforce.
Manish brings over two decades of HR leadership experience across diverse industries including pharmaceuticals, FMCG, banking, and technology.
His appointment signals Torrent’s commitment to aligning its people strategy with long-term business goals and fostering a high-performance, innovation-driven culture.
A Career Spanning Global HR Leadership
Before joining Torrent Pharma, Manish spent over a decade at Tata Consumer Products.
During his tenure, he held senior roles such as Senior Vice President – HR and Head of HR for International Business, based in the UK.
He led global talent transformation initiatives, succession planning, and organizational capability building across geographies.
His earlier career includes impactful stints at:
- GlaxoSmithKline Consumer Healthcare as GM – HR
- HSBC as Vice President – HR
- IBM as GM – HR, leading strategic HR in tech environments
- Hindustan Unilever Limited, where he spent six years in factory and branch HR roles
- Tata Motors, where he began his career as an engineer before transitioning to HR
Manish is an alumnus of XLRI Jamshedpur, one of India’s premier HR institutions.
His people-first approach and cross-sectoral experience are expected to play a key role in shaping Torrent’s evolving workforce strategy.
About Torrent Pharma
Torrent Pharmaceuticals Ltd., headquartered in Ahmedabad, is a flagship company of the Torrent Group and ranks among India’s top five pharmaceutical firms by market share.
Torrent has established a strong presence in cardiovascular, central nervous system, gastrointestinal, and diabetology segments.
This leadership has earned the company a reputation for quality, innovation, and strategic growth.
The company operates eight manufacturing facilities, five of which are USFDA-approved, and maintains a global footprint across more than 50 countries.
Torrent’s growth has been fueled by a series of strategic acquisitions, including Elder Pharma, Unichem Labs, Curatio Healthcare, and most recently JB Chemicals, which significantly expanded its reach in chronic therapies and the CDMO space.
With a robust pipeline, advanced R&D capabilities, and a commitment to sustainability, Torrent Pharma continues to shape the future of healthcare both in India and abroad.
Torrent Pharma recently received approval to conduct Phase III trials for Semaglutide tablets.
Alongside the appointment of Aman Mehta as Managing Director, these developments highlight the company’s ambition to lead in therapeutic innovation and organizational excellence.
Note: We are also on WhatsApp, LinkedIn, Google News, and YouTube, to get the latest news updates. Subscribe to our Channels. WhatsApp– Click Here, Google News– Click Here, YouTube – Click Here, and LinkedIn– Click Here.
